Logo image
Treat to Target, Remission and Low Disease Activity in the Treatment of Rheumatoid Arthritis
Journal article   Peer reviewed

Treat to Target, Remission and Low Disease Activity in the Treatment of Rheumatoid Arthritis

Martin Jan Bergman
Current treatment options in rheumatology, v 6(3), pp 260-267
01 Sep 2020

Abstract

Life Sciences & Biomedicine Rheumatology Science & Technology
Purpose of this reviewTreat to Target (T2T) and disease activity measurements have changed the way rheumatologists treat patients, particularly those with rheumatoid arthritis. The author will address the history behind the development of T2T as well as some practical aspects around the use of T2T and disease activity measurement.Recent findingsThe stated targets for disease activity are remission and low disease activity (LDA). However, given that these are "surrogate" measures, each individual measure may, in fact, be measuring a different level of disease activity. Ultimately, no single measure is better than any other. Despite this, recent work has demonstrated that patients in whom the target can be attained, there are better outcomes. How long to wait before making a change in therapy and how deep to push toward the absolute abrogation of disease remains unclear.SummaryTreat to Target is an attainable and acceptable goal for treating patients with rheumatoid arthritis. The deeper the response, the better the outcome, but a low level of disease activity may be acceptable. Treating patients to target will require that patients are evaluated, using a metric, and that changes are made in therapies, based on this metric and sound medical judgement.

Metrics

12 Record Views

Details

UN Sustainable Development Goals (SDGs)

This publication has contributed to the advancement of the following goals:

#3 Good Health and Well-Being

InCites Highlights

Data related to this publication, from InCites Benchmarking & Analytics tool:

Web of Science research areas
Rheumatology
Logo image